Thursday, 15 October 2026European Markets

THUNDERBIRD Stock Is 10% Down So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of THUNDERBIRD (AEX-Index: TBIRD.AS) fell by a staggering 10.56% to €0.08 at 14:09 EST on Tuesday, after two sequential sessions in a row of losses. AEX-Index is jumping 0.19% to €757.20, after two successive sessions in a row of gains. This seems, at the moment, a somewhat positive trend exchanging session today.

About THUNDERBIRD

Thunderbird Resorts, Inc., through its subsidiaries, engages in the gaming, hospitality, and real estate businesses in Nicaragua and Peru. It provides table and slot games, and sportsbooks. The company operates 3 slot parlors, 3 casinos, and 630 gaming positions. It develops, owns, and operates real estate properties; and rents office spaces. The company was formerly known as International Thunderbird Gaming Corporation and changed its name to Thunderbird Resorts, Inc. in July 2005. Thunderbird Resorts, Inc. was incorporated in 1987 and is headquartered in Panama, the Republic of Panama.

Earnings Per Share

As for profitability, THUNDERBIRD has a trailing twelve months EPS of €0.01.

PE Ratio

THUNDERBIRD has a trailing twelve months price to earnings ratio of 8.05. Meaning, the purchaser of the share is investing €8.05 for every euro of annual earnings.

Volume

Today's last reported volume for THUNDERBIRD is 42650 which is 18.55% below its average volume of 52364.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, THUNDERBIRD's stock is considered to be overbought (>=80).

Volatility

THUNDERBIRD's last week, last month's, and last quarter's current intraday variation average was 0.35%, 1.24%, and 7.28%.

THUNDERBIRD's highest amplitude of average volatility was 5.65% (last week), 6.21% (last month), and 7.28% (last quarter).

More news about THUNDERBIRD (TBIRD.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com